Literature DB >> 17439413

CB1 receptor activation in the basolateral amygdala produces antinociception in animal models of acute and tonic nociception.

Parisa Hasanein1, Mohsen Parviz, Mansoor Keshavarz, Kazem Javanmardi.   

Abstract

1. Recent studies have suggested that the basolateral nucleus of the amygdala (BLA) participates in the processing of pain information, especially noxious somatic information. Cannabinoid receptors or CB1 mRNA are expressed more in the BLA than in other nuclei of the amygdala. Thus, the aim of the present study was to examine whether CB1 receptors in the BLA may be involved in modulating acute and/or tonic nociceptive processing. 2. Adult rats were exposed to intra-BLA microinjection of the cannabinoid receptor agonist (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl) pyrrolo [1,2,3,-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone mesylate [WIN 55,212-2 (1, 2.5, 5 or 10 microg/side)] and subjected to the tail flick and formalin tests. 3. The rats demonstrated a dose-dependent increase in latency to withdraw from a thermal noxious stimulus in the tail flick test and a decrease in formalin-induced pain behaviours. The antinociceptive effects of the CB1 receptor agonist WIN 55,212-2 (10 microg/side) in both tests were attenuated in the presence of the selective CB1 receptor antagonist, N-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3- carboxamide (AM251; 0.55 ng/side). Administration of the CB1 receptor antagonist AM251 (0.55, 5.5, or 55.5 ng/side) alone did not alter the nociceptive thresholds in either test. Bilateral microinjection of the selective CB2 receptor antagonist N-[(1S)-endo-1,3,3-trimethyl bicyclo [2.2.1] heptan-2-yl]-5-(4-chloro-3-methylphenyl)-1-(4-methylbenzyl)-pyrazole-3-carboxamide (SR144528; 1 microg/side) had no effect on the antinociception produced by WIN 55,212-2, suggesting that the antinociceptive actions of WIN 55,212-2 are mediated by CB1 receptors. 4. The findings suggest the existence of a CB1-mediated inhibitory system in the BLA that, when activated, can diminish responsivity to acute and tonic noxious stimuli, but that normally has no tonic effect on the response threshold of these stimuli.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17439413     DOI: 10.1111/j.1440-1681.2007.04592.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  12 in total

Review 1.  Endocannabinoid signaling in the amygdala: anatomy, synaptic signaling, behavior, and adaptations to stress.

Authors:  T S Ramikie; S Patel
Journal:  Neuroscience       Date:  2011-08-22       Impact factor: 3.590

2.  Effects of GABAA receptors in nucleus cuneiformis on the cannabinoid antinociception using the formalin test.

Authors:  Junjie Chen; Parisa Hasanein; Alireza Komaki; Siamak Yari
Journal:  Psychopharmacology (Berl)       Date:  2021-03-13       Impact factor: 4.530

3.  A Novel Role for the Endocannabinoid System in Ameliorating Motivation for Alcohol Drinking and Negative Behavioral Affect after Traumatic Brain Injury in Rats.

Authors:  Elizabeth A Fucich; Jacques P Mayeux; M Adrienne McGinn; Nicholas W Gilpin; Scott Edwards; Patricia E Molina
Journal:  J Neurotrauma       Date:  2019-03-06       Impact factor: 5.269

Review 4.  Supraspinal modulation of pain by cannabinoids: the role of GABA and glutamate.

Authors:  K Rea; M Roche; D P Finn
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

5.  CB1 Cannabinoid Agonist (WIN55,212-2) Within the Basolateral Amygdala Induced Sensitization to Morphine and Increased the Level of μ-Opioid Receptor and c-fos in the Nucleus Accumbens.

Authors:  Marzieh Molaei; Zahra Fatahi; Jalal Zaringhalam; Abbas Haghparast
Journal:  J Mol Neurosci       Date:  2016-01-23       Impact factor: 3.444

6.  Activation of CB2 receptors as a potential therapeutic target for migraine: evaluation in an animal model.

Authors:  Rosaria Greco; Antonina Stefania Mangione; Giorgio Sandrini; Giuseppe Nappi; Cristina Tassorelli
Journal:  J Headache Pain       Date:  2014-03-17       Impact factor: 7.277

7.  The CB1 receptor antagonist AM251 impairs reconsolidation of pavlovian fear memory in the rat basolateral amygdala.

Authors:  Patrizia Ratano; Barry J Everitt; Amy L Milton
Journal:  Neuropsychopharmacology       Date:  2014-05-07       Impact factor: 7.853

8.  Evidence for a novel functional role of cannabinoid CB(2) receptors in the thalamus of neuropathic rats.

Authors:  M D Jhaveri; S J R Elmes; D Richardson; D A Barrett; D A Kendall; R Mason; V Chapman
Journal:  Eur J Neurosci       Date:  2008-04       Impact factor: 3.386

9.  Microinjection of WIN55,212-2 as A Cannabinoid Agonist into The Basolateral Amygdala Induces Sensitization to Morphine in Rats.

Authors:  Marzieh Molaei; Mohammad-Hossein Sanati; Jalal Zaringhalam; Abbas Haghparast
Journal:  Basic Clin Neurosci       Date:  2014-10

Review 10.  Brain CB₂ Receptors: Implications for Neuropsychiatric Disorders.

Authors:  Michelle Roche; David P Finn
Journal:  Pharmaceuticals (Basel)       Date:  2010-08-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.